{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ADC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.045,"timestamp":1745302320000,"preClose":0.041,"halted":0,"volume":45000,"delay":0,"nameEN":"ACDC Metals Ltd","floatShares":39337511,"shares":73275130,"eps":-0.005605,"marketStatus":"Not Yet Opened","change":0.004,"latestTime":"04-22 16:12:00 AEST","open":0.042,"high":0.045,"low":0.042,"amount":1950,"amplitude":0.073171,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.005605,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.041,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":1.4075343715952446,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":39337511,"roa":"-3.02%","roe":"-3.81%","lyrEps":-0.006941,"volumeRatio":1.4075343715952446,"shares":73275130,"dividePrice":0,"high":0.045,"amplitude":0.073171,"preClose":0.041,"low":0.042,"week52Low":0.041,"pbRate":"0.31","psRate":"-136.78","week52High":0.095,"institutionHeld":0,"latestPrice":0.045,"eps":-0.005605,"divideRate":0,"volume":45000,"delay":0,"ttmEps":-0.005605,"open":0.042,"prevYearClose":0.055,"prevWeekClose":0.041,"prevMonthClose":0.045,"prevQuarterClose":0.045,"fiveDayClose":0.042,"twentyDayClose":0.045,"sixtyDayClose":0.053},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ADC.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522134338","title":"Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522134338","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522134338?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:44","pubTimestamp":1743061459,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology  said its novel CD228-directed antibody-drug conjugate , BA1302, received Orphan Drug Designation  from the Food and Drug Administration  for the treatment of squamous non-small cell lung cancer  and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.The biopharmaceutical company's shares were up 2% in recent trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","06955","BK4183","ADC.AU","ODD","BK4231","ADC","BK1161","BK7095"],"gpt_icon":0},{"id":"2520635265","title":"Otsuka's Taiho to Buy Swiss ADC Developer Araris Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2520635265","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520635265?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:06","pubTimestamp":1742256371,"startTime":"0","endTime":"0","summary":"Otsuka Holdings  said its unit, Taiho Pharmaceutical, will acquire Swiss biotech firm Araris Biotech for up to $1.14 billion to strengthen its antibody-drug conjugate  pipeline, according to a Monday filing on the Tokyo Stock Exchange.Taiho will pay $400 million upfront and potential additional milestone payments of up to $740 million. The deal is expected to close in the first half of 2025.Price : $7712.00, Change: $+94, Percent Change: +1.23%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK4231","ADC","BK7095","ADC.AU"],"gpt_icon":0},{"id":"2517185242","title":"CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185242?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:46","pubTimestamp":1741243589,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  submitted the Phase I-B trial application in Australia for its large B-cell lymphoma  drug, according to a Thursday filing with the Hong Kong bourse.CS5001 is an ROR1-targeting antibody-drug conjugate  that works with first-line standard-of-care  to diffuse large B-cell lymphoma , the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK4080","BK1574","02616","BK4231","XJO.AU","XAO.AU","ADC.AU","ADC","BK1161","XKO.AU"],"gpt_icon":0},{"id":"2516576704","title":"Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516576704","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516576704?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:21","pubTimestamp":1740975711,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  said the first patient was enrolled in its phase three trial for BL-B01D1, according to a Monday filing with the Shanghai bourse.BL-B01D1 is a dual antibody-drug conjugate  combined with Osimertinib for treating EGFR-mutated advanced non-small cell lung cancer.Shares of the pharmaceutical company were down 4% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","ADC.AU","BK7095","BK4080","BK0239","688506","BK4231"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[]}}